Intervention not reported
Sclerotherapy(No direct RCT) · people with liver cirrhosis and oesophageal varices with no history of bleeding
It is very uncertain whether the intervention changes sclerotherapy(No direct RCT) (very low certainty).
1 finding from 1 review
OR 1.19 [0.02, 80.24]
Studies not reported
Very low
Intervention not reported
Sclerotherapy(2 RCTs, 90 participants) · people with liver cirrhosis and oesophageal varices with no history of bleeding
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Intervention not reported
Sclerotherapy(1 RCT, 141 participants) · people with liver cirrhosis and oesophageal varices with no history of bleeding
It is very uncertain whether the intervention changes sclerotherapy(1 RCT, 141 participants) (very low certainty).
1 finding from 1 review
HR 0.91 [0.44, 1.95]
Studies not reported
Very low
Intervention not reported
Beta‐blockers + sclerotherapy(1 RCT, 141 participants) · people with liver cirrhosis and oesophageal varices with no history of bleeding
It is very uncertain whether the intervention changes beta‐blockers + sclerotherapy(1 RCT, 141 participants) (very low certainty).
1 finding from 1 review
HR 0.92 [0.41, 2.08]
Studies not reported
Very low
Intervention not reported
Sclerotherapy(3 RCTs, 175 participants) · people with liver cirrhosis and oesophageal varices with no history of bleeding
It is very uncertain whether the intervention changes sclerotherapy(3 RCTs, 175 participants) (very low certainty).
1 finding from 1 review
HR 1.02 [0.33, 3.27]
Studies not reported
Very low
Intervention not reported
Sclerotherapy(5 RCTs, 320 participants) · people with liver cirrhosis and oesophageal varices with no history of bleeding
It is very uncertain whether the intervention changes sclerotherapy(5 RCTs, 320 participants) (very low certainty).
1 finding from 1 review
HR 1.35 [0.95, 1.92]
Studies not reported
Very low
Intervention not reported
Beta‐blockers + sclerotherapy(2 RCTs, 167 participants) · people with liver cirrhosis and oesophageal varices with no history of bleeding
The intervention may leads to higher beta‐blockers + sclerotherapy(2 RCTs, 167 participants) (low certainty).
1 finding from 1 review
HR 2.08 [1.03, 4.08]
Studies not reported
Low
Intervention not reported
Sclerotherapy plus Variceal band ligation(No direct RCT) · people with liver cirrhosis and previous oesophageal variceal bleeding
The intervention showed no clear difference in sclerotherapy plus Variceal band ligation(No direct RCT) (low certainty).
1 finding from 1 review
HR 0.78 [0.35, 1.76]
Studies not reported
Low
Intervention not reported
Sclerotherapy plus Nitrates(1 RCT; 76 participants) · people with liver cirrhosis and previous oesophageal variceal bleeding
The intervention probably leads to lower sclerotherapy plus Nitrates(1 RCT; 76 participants) (moderate certainty).
1 finding from 1 review
HR 0.19 [0.02, 0.86]
Studies not reported
Moderate
Intervention not reported
Beta‐blockers plus Sclerotherapy(No direct RCT) · people with liver cirrhosis and previous oesophageal variceal bleeding
It is very uncertain whether the intervention changes beta‐blockers plus Sclerotherapy(No direct RCT) (very low certainty).
1 finding from 1 review
OR 1.29 [0.28, 5.7]
Studies not reported
Very low
Intervention not reported
Beta‐blockers plus Sclerotherapy(2 RCTs; 71 participants) · people with liver cirrhosis and previous oesophageal variceal bleeding
The intervention showed no clear difference in beta‐blockers plus Sclerotherapy(2 RCTs; 71 participants) (low certainty).
1 finding from 1 review
OR 1.46 [0.36, 6.06]
Studies not reported
Low
Intervention not reported
Sclerotherapy · people with liver cirrhosis and previous oesophageal variceal bleeding
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Beta‐blockers plus Sclerotherapy(2 RCTs; 128 participants) · people with liver cirrhosis and previous oesophageal variceal bleeding
The intervention showed no clear difference in beta‐blockers plus Sclerotherapy(2 RCTs; 128 participants) (low certainty).
1 finding from 1 review
Intervention not reported
Beta‐blockers plus Sclerotherapy(1 RCT; 40 participants) · people with liver cirrhosis and previous oesophageal variceal bleeding
It is very uncertain whether the intervention changes beta‐blockers plus Sclerotherapy(1 RCT; 40 participants) (very low certainty).
1 finding from 1 review
HR 1.26 [0.17, 10.1]
Studies not reported
Very low
Intervention not reported
Beta‐blockers plus sclerotherapy(4 RCTs; 231 participants) · people with liver cirrhosis and previous oesophageal variceal bleeding
The intervention probably leads to lower beta‐blockers plus sclerotherapy(4 RCTs; 231 participants) (moderate certainty).
1 finding from 1 review
HR 0.6 [0.37, 0.95]
Studies not reported
Moderate
Intervention not reported
Sclerotherapy plus variceal band ligation(No direct RCT) · people with liver cirrhosis and previous oesophageal variceal bleeding
The intervention showed no clear difference in sclerotherapy plus variceal band ligation(No direct RCT) (low certainty).
1 finding from 1 review
HR 1.83 [0.46, 7.4]
Studies not reported
Low
Intervention not reported
Beta‐blockers plus Sclerotherapy(8 RCTs; 370 participants) · people with liver cirrhosis and previous oesophageal variceal bleeding
The intervention showed no clear difference in beta‐blockers plus Sclerotherapy(8 RCTs; 370 participants) (low certainty).
1 finding from 1 review
HR 0.69 [0.43, 1.09]
Studies not reported
Low
Long‐term recurrence (> 5 years) · people with GSV incompetence
It is very uncertain whether endovenous laser ablation (EVLA) changes long‐term recurrence (> 5 years) compared with ultrasound‐guided foam sclerotherapy (UGFS) (very low certainty).
1 finding from 1 review
Complications (up to 8 years) · people with GSV incompetence
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
QoL · people with GSV incompetence
1 finding from 1 review
no estimate extracted
Studies not reported
Moderate